Allergy vaccines a review of developments

Clinical Immunotherapeutics

Volumn 6, Issue 2, 1996, Pages 130-142

  Hellman, Lars ^a   Carlsson, Mats ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CARRIER PROTEIN; CYTOKINE; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; PEPTIDE; VACCINE;

ALLERGY; ANTIGEN ANTIBODY COMPLEX; ATOPY; DESENSITIZATION; IMMUNE RESPONSE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0029787026     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259509     Document Type: Article

References (97)

1. Knight SC, Stagg AJ. Antigen-presenting cell types. Curr Opin Immunol 1993:5:374-82
2. RomagnianiS. Induction of TH1 and TH2 responses: a key role for the 'natural'immune response? Immunol Today 1992; 13: 379-81
3. Punnonen J, Aversa GO, Cocks BG, et al. Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sei USA 1993; 909: 3730-4
4. Ricci M. IL-4: a key cytokine in atopy. Clin Exp Allergy 1994; 24: 801-12
5. Kelso A. Thl and Th2 subsets: paradigms lost? Immunol Today 1995; 16:374-9
6. Kay B. T lymphocytes and their products in atopic allergy and asthma. Int Arch Allergy Appl Immunol 1991 ; 94: 189-93
7. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992; 13: 501-7
8. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304
9. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; II: 1572-3
10. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 11:814-7
11. Nakagawa T, Gershwin ME. Immunotherapy of allergic diseases. Int Arch Allergy Immunol 1993; 102: 117-20
12. Ohman JL. Allergen immunotherapy. Clin Allergy 1992; 76: 977-91
13. Food and Drug Administration. PDA notes. November 1988
14. Golden DBK, Lawrence ID, Hamilton RH, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992:90:386-93
15. Müller U, Morris T, Bischof M, et al. Combined active and passive immunotherapy in honey-bee-sting allergy. J Allergy Clin Immunol 1986:78: 115-22
16. Sehon AH. Suppression of IgE antibody responses with tolerogenic conjugates of allergens and haptens. Prog Allergy 1982;32: 161-202
17. Dreborg S, Akerblom E. Immunotherapy with monomethoxypolyethylene glycol modified allergens. CRC Crit Rev Ther Drug Carrier Syst 1990; 6: 315-65
18. HayGlass KT, Stefura BP. Anti-interferon y treatment blocks the ability of glutaraldehyde-polymerized allergens to inhibit specific IgE responses. J Exp Med 1991; 173: 279-85
19. Gieni RS, Yang X, HayGlass KT. Allergen-specific modulation of cytokine synthesis patterns and IgE responses in vivo with chemically modified allergen. J Immunol 1993; 150: 302-10
20. Yang X, Gieni RS, Mosmann TR, et al. Chemically modified antigen preferentially elicits induction of Thl-like cytokine synthesis patterns in vivo, i Exp Med 1993; 178: 349-53
21. HayGlass KT, Stefura BP. Antigen-specific inhibition of ongoing murine IgE responses 11. Inhibition of IgE responses induced by treatment with glutaraldehyde-modified allergens is paralleled by reciprocal increases in IgG2a synthesis. J Immunol 1991; 147:2455-60
22. Gieni RS, HayGlass KT. Regulation of murine IgE responses: induction of long-lived inhibition of allergen-specific responses is genetically restricted. Cell Immunol 1991; 138: 64-78
23. Machiels JJ, Somville MA, Lebrun PM, et al. Allergic bronchial asthma due to Dermatophagoides pteronvxxinu.'i hypersensitivity can be efficiently treated by inoculation of allergenantibody complexes, J Clin Invest 1990; 85: 1024-35
24. Saint-Remy J-MR. Novel approaches in immunotherapy. Clin Rev Allergy 1994; 12: 23-42
25. Machiels JJ, Lebrun PM, Jacquemin MG, et al. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronvssinus-sensilive allergic asthma under therapy with allergen-antibody complexes. Am Rev RespirDis 1993; 147: 1407-12
26. Thepen T, McMenamin C, Oliver), et al. Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs immunity. Eur J Immunol 1991; 21:2845-50
27. Manca F, Fenoglio D, Kunkl A, et al. Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. J Immunol 1988; 140: 2893-8
28. Manca F, Fenoglio D, Li Pira G, et al. Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med 1991; 173:37-48
29. Heyman B. The immune complex: possible ways of regulating the antibody response. Immunol Today 1990; 11: 310-3
30. Hanson DG. Ontogeny of orally induced tolerance to soluble proteins in mice I. Priming and tolerance in newborns. J Immunol 1981;127: 1518-24
31. Mowat AM. The regulation of immune responses to dietary protein antigens. Immunol Today 1987; 8: 93-8
32. Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization. Allergy 1985; 40: 321-35
33. Taudorf E, Laursen LC, Lanner A, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987; 80: 153-61
34. Taudorf E, Möller C, Russell MW. Secretory IgA response in oral immunotherapy. Investigation in birch pollinosis. Allergy 1994:49:760-5
35. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allerg Clin Immunol 1994; 93: 61-7
36. Holt PG. Immunoprophylaxis of atopy: light at the end of the tunnel? Immunol Today 1994; 15: 484-9
37. Holt PC. A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet 1994; 344: 456-8
38. Hoiseth SK. Stoker BAD. Aromatic-dependent Salmonella typhinuii'iuni are non-virulent and effective as live vaccines. Nature 1981:291:238
39. Valenta R. Duchéne M. Vrtala S. et al. Recombinant allergens as candidates for immunotherapy of type I allergic diseases. Vaccines 1993:93: 37-42
40. Litwin A. Pesce AJ, Michael JG. Regulation of the immune response to allergens by immunosuppressive allergenic frag ments. I. Peptic fragment of honey bee venom phospholipase A2. Int Arch Allergy Appl Immunol 1988; 87: 361-6
41. O'Hehir RE. Carman RD, Greenstein JL. el al. The specificity and regulation of T-cell responsiveness to allergens. Ann Rev Immunol 1991; 9: 67-95
42. Schwartz RH. T cell anergy. When cells of the immune system 'see' antigens in the absence of the right cosignais, they shut themselves down instead of attacking. Further therapies might capitalize on that reaction. Sei Am 1993 Aug: 48-54
43. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 14: 937-44
44. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990: 248: 1349-56
45. Lamb JR, Skidmore BJ, Green N, et al. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983: 157: 1434-47
46. Hsieh KH. Altered interleukin 2 (IL-2) production and responsiveness after hyposensitization to house dust. J Allergy Clin Immunol 1985:76: 188-94
47. Hsieh KH. Decreased expression of high affinity interleukin 2 receptor after hyposensitization to house dust. Ann Allergy 1987:59: 57-62
48. Mohapatra SS. Modulation of allergen-specific antibody responses by T-cell-hased peptide vaccine(s). Clin Rev Allergy 1994; 12: 3-22
49. O'Hehir RE. Hoyne GF. Thomas WR, et al. House dust mile allergy: from T-cell epitopes to immunotherapy. Eur J Clin Invest 1993:23: 763-72
50. Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy 1994; 49: 302-8
51. Norman PS. Modern concepts of immunotherapy. Curr Opin Immunol 1993: 5: 968-73
52. Schad VC. T cell tolerance: models lor clinical application to allergy and autoimmunity. Mech Immune Regul 1994: 58: 193-205
53. O'Hehir RE. Lamb JR. Induction of specific clonal anergy in human T lymphocytes by Staph\loc
54. O'Hehir RE. Yssel H, Verma S. et al. Clonal analysis of differential lymphokine production in peptide and superantigen in ducedTcell anergy. Int Immunol 1991: 3: 819-26
55. Lake RA, O'Hehir RE. Verhoef A. et ul. CD28 messenger RNA rapidly decays when activated T-cells are functionally anergized with specific peptide. Inl Immunol 1993: 5: 461-6
56. Lombardi G, Sidhu S. Batchelor R, et al. Anergic T cells as suppressor cells in vitro. Science 1994: 264: 1587-9
57. Hoyne GF. O'Hehir RE, Wraith DC. et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993: 178: 1783-8
58. Holt PC. McMenainin C. Defence against allergic sensitization in the healthy lung: the role of inhalation tolerance. Clin Exp Allergy 1989; 19:255-62
59. McMenainin C, Schon Hegrad M. Oliver J, et al. Regulation of IgE responses to inhaled antigens: cellular mechanisms underlying allergic sensitization versus tolerance induction, hit Arch Allergy Appl Immunol 1991:94:78-82
60. Morgenstern JP. Griffith U. Brauer AW. et al. Amino acid sequence of Fei dl. the major allergen of the domestic cat: protein sequence and cDNA cloning. Proc Natl Acad Sei USA 1991:88:9690-4
61. Rogers BL. Morgenstern JP. Garman RD. et al. Recombinant Fei dl: expression, purification. IgE binding and reaction with cat-allergic human T cells. Mol Immunol 1993; 30: 559-68
62. BrinerTJ, Kuo MC. Keating KM, et al. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Eel dl. Proc Natl Acad Sei USA 1993; 90: 7608-12
63. Norman PS. Ohman JL. Long AA. et al. Early clinical experi ence with T cell reactive peptides from cat allergen Pel dl (abstract]. J Allergy Clin Immunol 1994: 93: 231
64. Norman PS. Ohman JL, Long AA. et al. Follow on .study of the first clinical trial with T cell defined peptides from cat allergen Pel dl |abstract). J Allergy Clin Immunol 1995: 95: 259.
65. Vercelli D, Geha RS. Regulation of IgE synthesis in humans: a tale of two signals. J Allergy Clin Immunol 1991 ; 88: 285-97
66. Jabara HH. Fu SM, Geha RS. et al. CD40 and IgE: synergism between anti-CD40 and IgE: synergism between anti-CD4() monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990: 172: 1861-4
67. Spriggs MK. Armitage RJ. Strockbine L. et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992; 176: 1543 50
68. Fuleihan R. Ramesh N. Geha RS. Role of CD40-CD4()-ligand interaction in Ig-isotypc switching. Curr Opin Immunol 1993; 5: 963-7
69. Bradding P. Feather 1H, Howarth PH. et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992: 176: 1381-6
70. Brunner T. Heusser CH. Dahinden CA. Human peripheral blood basophils primed by interleukin 3 IIL-3) produce IL-4 in response to immunoglohulin E receptor stimulation. J Exp Med 1993: 177: 605-11
71. Arock M. Merle-Beral H. Dugas B, et al. IL-4 release by human leukemic and activated normal basophils. J Immunol 1993; 151: 1441-7
72. Gauchat JF. Henchoz S. Mazzei G. et al. Induction of human IgE synthesis in B-cells by mast cells and basophils. Nature 1993: 365: 340-3
73. Kruse N. Tony HP. Sebald W. Conversion of human interleukin-4 into high affinity antagonist by a single amino acid replacement. EMBO J 1993: II: 3237-44
74. AversaG. Punnonen J. Cocks BG. etal. An interleukin 4 (IL-41 mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G6 ( IgG4 ) and IgE synthesis and B cell proliferation: support for a common component shared by !L-4 and IL 13. J Exp Med 1993; 178: 2213-8
75. Hellman L. Characterization of four novel £chain inRNA and a comparative analysis of genes for immunoglobulin E in rodents and man. Eur J Immunol 1993: 23: 159-67
76. Hagan P, Blumenthal UJ, Dünn D, et al. Human IgE, IgG4 and resistance to infection with Schistosoma haemalobium. Nature 1991:349:243-5
77. Dünne DW, Butterworth AE, Fulford AJC, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to infection. Eur J Immunol 1992; 22: 1483-94
78. Sutton BJ, Could HJ. The human IgE network. Nature 1993; 366:421-8
79. Heyman B, Tianmin L, Gustavsson S. In vivo enhancement of the specific antibody response via the low-affinity receptor for IgE. Eur J Immunol 1993; 23: 1739-42
80. Kühn R, Rajevsky K, Müller W. Generation and analysis of IL-4 deficient mice. Science 1991; 254: 707-10
81. Haba S, Nisonoff A. Inhibition of IgE synthesis by anti-IgE: role of long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc Natl Acad Sei USA 1990; 87:3363-7
82. Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol 1994; 24:415-20
83. Levy DA, Chen J. Healthy IgE-deficient person. N Engl J Med I970;283:541
84. Helm B, Marsh P, Vercelli D, et al. The mast cell binding site on human immunoglobulin E. Nature 1988; 331: 180-3
85. Helm B, Kebo D, Vercelli D, et al. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human e-chain fragment of 76 amino acids. Proc Natl Acad Sei USA I989; 86: 9465-9
86. Presta LG, Lahr Si, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-32
87. Chang TW, Davis FM, Sun N-C, et al. Monoclonal antibodies specific for human IgE-producing B-cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/Technology 1990; 8: 122-6
88. Davis FM, Gossett LA, Pinkston KL, et al. Can anti-IgE be used to treat allergy? Springer Semin Immunopathol 1993; 15: 51-73
89. Froehlich J, Schoenhoff M, Jardieu P, et al. Multiple doses of a recombinant humanized monoclonal anti IgE antibody are safely tolerated and decreased free serum IgE to undetectable levels [abstract no. 863). J Allergy Clin Immunol 1995; 95: 356
90. Bates D, Ruppel J, Fei BAD, et al. Pharmacokinetics/dynamics following administration of recombinant humanized monoclonal anti IgE antibody in Cynomolgus monkey [abstract no. 864). J Allergy Clin Immunol 1995; 95: 365
91. Haba S, Nisonoff A. Induction of high titers of anti-IgE by immunization of inbred mice with syngeneic IgE. Proc Natl Acad Sei USA 1987; 84: 5009-13
92. Haba S, Nisonoff A. Immunological responsiveness of neonatal A/J mice to isotypic determinants of syngeneic IgE. J Exp Med 1988; 168:713-24
93. Haba S, Nisonoff A. Role of antibody and T cells in the longterm inhibition of IgE synthesis. Proc Natl Acad Sei USA 1994; 91: 604-8
94. Haba S, Nisonoff A. Effect of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J Immunol 1994; 152: 51-7
95. Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats. I. Effects on serum IgE concentrations. Eur J Immunol 1985; 15: 272-7
96. Marshall JS, Prout SJ, Jaffery G, et al. Induction of an autoanti-IgE response in rats. II. Effects on mast cell populations. Eur J Immunol 1987; 17: 445-51
97. Marshall JS, BellEB. Induction of an auto-anti-IgE response in rats. III. Inhibition of a specific IgE response. Immunology 1989; 66: 428-33